Abstract
Background: Hypertension is considered a major health problem in patients with chronic kidney disease (CKD) as approximately 80-85% of CKD patients’ suffer from hypertension in the United States. Hypertension is the second leading cause of CKD after diabetes and is strongly related to morbidity and mortality. It has been found that there is a relation among hypertension, glomerular filtration rate (GFR) and creatinine levels.
Objective: Since there is a strong relation between hypertension and CKD, and hypertension seems to lead to cardiovascular diseases, which have epidemic proportions in CKD, this review article discusses the etiology of hypertension and the existing optimal therapies that contribute to the hypertension and heart rate management.
Results: There are many approaches that contribute to the management of hypertension and heart rate in CKD patients. Lifestyle modifications in combination with drug therapy lead to the better control of hypertension in CKD patients.
Conclusion: Hypertension is strongly related to cardiovascular diseases in CKD patients. Since this relation exists and hypertension leads to cardiovascular diseases, the management of hypertension and increased heart rate should be a main therapeutic target in these patients.
Keywords: Hypertension, chronic kidney disease, treatment, heart rate, diabetes, cardiovascular diseases.
Current Pharmaceutical Design
Title:Management of Blood Pressure and Heart Rate in Chronic Kidney Disease
Volume: 23 Issue: 31
Author(s): Antonia Kaltsatou*
Affiliation:
- School of Physical Education & Sport Science, University of Thessaly, Karies, 42100, Trikala,Greece
Keywords: Hypertension, chronic kidney disease, treatment, heart rate, diabetes, cardiovascular diseases.
Abstract: Background: Hypertension is considered a major health problem in patients with chronic kidney disease (CKD) as approximately 80-85% of CKD patients’ suffer from hypertension in the United States. Hypertension is the second leading cause of CKD after diabetes and is strongly related to morbidity and mortality. It has been found that there is a relation among hypertension, glomerular filtration rate (GFR) and creatinine levels.
Objective: Since there is a strong relation between hypertension and CKD, and hypertension seems to lead to cardiovascular diseases, which have epidemic proportions in CKD, this review article discusses the etiology of hypertension and the existing optimal therapies that contribute to the hypertension and heart rate management.
Results: There are many approaches that contribute to the management of hypertension and heart rate in CKD patients. Lifestyle modifications in combination with drug therapy lead to the better control of hypertension in CKD patients.
Conclusion: Hypertension is strongly related to cardiovascular diseases in CKD patients. Since this relation exists and hypertension leads to cardiovascular diseases, the management of hypertension and increased heart rate should be a main therapeutic target in these patients.
Export Options
About this article
Cite this article as:
Kaltsatou Antonia*, Management of Blood Pressure and Heart Rate in Chronic Kidney Disease, Current Pharmaceutical Design 2017; 23(31) . https://dx.doi.org/10.2174/1381612823666170829164305
DOI https://dx.doi.org/10.2174/1381612823666170829164305 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Heme-Heme Oxygenase System in Wound Healing; Implications for Scar Formation
Current Drug Targets Is Beta-Blocker Treatment Associated with a Decrease in the Risk of Cancer
Letters in Drug Design & Discovery The Dialogue Between Endothelial Cells and Monocytes/Macrophages in Vascular Syndromes
Current Pharmaceutical Design Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review
Current Vascular Pharmacology Renal and Hepatic Transporter Expression in Type 2 Diabetic Rats
Drug Metabolism Letters Bioactive Small Molecules: Promising Novel Therapies in Cardiovascular Diseases – PART II
Current Topics in Medicinal Chemistry Cilostazol: A New Drug in the Treatment Intermittent Claudication
Recent Patents on Cardiovascular Drug Discovery Editorial [Hot Topic: Natural Products for the Healthy Heart (Guest Editor : Dipak K. Das)]
Current Pharmaceutical Biotechnology Hormone Replacement Therapy and Stroke
Current Vascular Pharmacology Therapeutic Perspectives in the Antiphospholipid Syndrome
Current Rheumatology Reviews Exploitation of Novel Molecular Targets to Treat Idiopathic Pulmonary Fibrosis: A Drug Discovery Perspective
Current Medicinal Chemistry Hypertension in Pregnancy: Clinical Manifestations and Treatment
Current Hypertension Reviews Editorial (Thematic Issue: Current Research, Knowledge and Controversies on High Density Lipoprotein)
Current Medicinal Chemistry Impact of Inhibitors of the Renin-Angiotensin-Aldosterone System on Liver Fibrosis and Portal Hypertension
Current Medicinal Chemistry Primary and Secondary Hypertriglyceridaemia
Current Drug Targets An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review
Current Diabetes Reviews The Role of Adipocytokines in Atherogenesis and Atheroprogression
Current Drug Targets Statins Attenuate Fibrotic Manifestations of Cardiac Tissue Damage
Current Molecular Pharmacology Nerve Growth Factor: A Focus on Neuroscience and Therapy
Current Neuropharmacology L-Arginine Analogs – Inactive Markers or Active Agents in Atherogenesis?
Cardiovascular & Hematological Agents in Medicinal Chemistry